Related Experiment Video
Updated: Mar 6, 2026
12:04
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
29.6K
Therapeutic Challenges in Neuroendocrine Tumors.
Ioannis Legakis1, Muhammad Wasif Saif2, Kostantinos Syrigos1
1Oncology Unit, 3rd Department of Internal Medicine, Sotiria General Hospital, Athens School of Medicine, Athens. Greece.
Anti-Cancer Agents in Medicinal Chemistry
|March 9, 2017
Summary
Neuroendocrine tumors (NETs) are increasingly diagnosed, often with metastases. Advances in molecularly-targeted therapies offer new management strategies for these complex cancers.
Area of Science:
- Oncology
- Endocrinology
- Genetics
Background:
- Neuroendocrine tumors (NETs) are a genetically diverse cancer group.
- NETs can manifest with hormone-related symptoms or remain clinically silent.
- Increasing incidence and delayed diagnosis, often at metastatic stages, complicate management.
Purpose of the Study:
- To highlight the increasing incidence and diagnostic challenges of NETs.
- To discuss the evolving therapeutic landscape for NETs, including molecularly-targeted therapies.
- To emphasize the need for multidisciplinary specialist involvement in NET patient care.
Main Methods:
- Review of current clinical statistics on NET frequency and occurrence.
- Analysis of recent advancements in molecularly-targeted therapies for oncology.
- Discussion of the importance of multidisciplinary care in managing NETs.
Main Results:
- NETs exhibit significant genetic heterogeneity and varied clinical presentations.
- Diagnosis frequently occurs at advanced stages, necessitating complex, long-term management.
- The evolution of targeted therapies is creating new avenues for NET treatment.
Conclusions:
- Despite therapeutic advances, early diagnosis of NETs remains a challenge.
- Molecularly-targeted therapies represent a significant development in NET management.
- A collaborative, multidisciplinary approach is crucial for optimizing outcomes in NET patients.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
698
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
698
02:17The Tumor Microenvironment
8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K